Akari Therapeutics Plc
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
AKTX$7.66+3.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Shareholders’ Equity
(amounts in thousands, except share data)
| Accumulated | |||||||
|---|---|---|---|---|---|---|---|
| Additional · Capital · Other · Total | |||||||
| Share Capital · Paid-in- · Redemption · Comprehensive · Accumulated · Shareholders’ | |||||||
| Shares | Amount | Capital | Reserve | Loss | Deficit | Equity | |
| Balance, December 31, 2025 | 90,536,879,533 | $— | $234,318 | $59,342 | $(782) | $(264,550) | $28,328 |
| Issuance of share capital related to financing, net of issuance costs | 1,030,130,000 | — | 188 | — | — | — | 188 |
| Stock-based compensation | — | — | 305 | — | — | — | 305 |
| Foreign currency translation | — | — | — | — | 14 | — | 14 |
| Net loss | — | — | — | — | — | (14,455) | (14,455) |
| Balance, March 31, 2026 | 91,567,009,533 | — | 234,811 | 59,342 | (768) | (279,005) | 14,380 |
| Issuance of share capital related to financing, net of issuance costs | 21,127,920,000 | — | 5,203 | — | — | — | 5,203 |
| Issuance of share capital for warrant exercises, net of issuance costs | 27,337,840,000 | 1 | 3,034 | — | — | — | 3,035 |
| Stock-based compensation | — | — | 711 | — | — | — | 711 |
| Foreign currency translation | — | — | — | — | 73 | — | 73 |
| Net loss | — | — | — | — | — | (4,807) | (4,807) |
| Balance, June 30, 2026 | 140,032,769,533 | $1 | $243,759 | $59,342 | $(695) | $(283,812) | $18,595 |
| Accumulated | |||||||
|---|---|---|---|---|---|---|---|
| Additional · Capital · Other · Total | |||||||
| Share Capital · Paid-in- · Redemption · Comprehensive · Accumulated · Shareholders’ | |||||||
| Shares | Amount | Capital | Reserve | Loss | Deficit | Equity | |
| Balance, December 31, 2024 | 53,186,919,523 | $5,319 | $212,706 | $52,194 | $(738) | $(247,252) | $22,229 |
| Issuance of share capital related to financing, net of issuance costs | 4,566,062,000 | 457 | 1,785 | — | — | — | 2,242 |
| Stock-based compensation | — | — | 1,015 | — | — | — | 1,015 |
| Foreign currency translation | — | — | — | — | (35) | — | (35) |
| Net loss | — | — | — | — | — | (3,705) | (3,705) |
| Balance, March 31, 2025 | 57,752,981,523 | 5,776 | 215,506 | 52,194 | (773) | (250,957) | 21,746 |
| Issuance of share capital related to financing, net of issuance costs | 5,753,878,000 | 575 | 3,829 | — | — | — | 4,404 |
| Issuance of share capital on conversion of convertible notes, related party | 387,880,000 | 39 | 270 | — | — | — | 309 |
| Issuance of share capital for payments in kind | 1,002,900,000 | 100 | 522 | — | — | — | 622 |
| Vesting of restricted shares | 331,822,000 | 33 | — | — | — | — | 33 |
| Stock-based compensation | — | — | 719 | — | — | — | 719 |
| Foreign currency translation | — | — | — | — | (333) | — | (333) |
| Net loss | — | — | — | — | — | (1,895) | (1,895) |
| Balance, June 30, 2025 | 65,229,461,523 | $6,523 | $220,846 | $52,194 | $(1,106) | $(252,852) | $25,605 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.